Jasvinder Singh, MD, MPHProfessor of Medicine and Epidemiology
Endowed Professor, Musculoskeletal Outcomes Research


Faculty Office Tower, room 805B
Birmingham, AL 35294-0000
Telephone: (205) 934-0315
Fax: (205) 996-9685




Bachelor of Medicine and Bachelor of Surgery (MBBS), University College of Medical Sciences, New Delhi, India, 1988-1993
Master of Public Health (Epidemiology), University of Minnesota, Minneapolis, MN, 2001-2003
Residency (Psychiatry), All India Institute of Medical Sciences (AIIMS), New Delhi, India , 1994
Residency (Internal Medicine), State University of New York (SUNY), Syracuse, NY, 1995-1998
Fellowship (Rheumatology), Washington University School of Medicine & Barnes Jewish Hospital, St. Louis, MO, 1998-2001


Research Interests

Dr. Singh is involved in performing studies of comparative effectiveness of treatments and outcomes research in rheumatic diseases, with a focus on gout, osteoarthritis, lupus and joint replacement. He is performing Cochrane reviews and network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis and other therapies for rheumatic diseases. He is also conducting studies of patient-reported outcomes in patients with various forms of arthritis, in particular osteoarthritis, joint replacement and gout.



Click here for a more complete list of publications. Below are a few selected papers.

Singh JA, Hossain A, Tanjong Ghogomu E, et al. 2017. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 3:CD012591. PMID: 28282491.

Singh JA, Saag KG, Bridges SL, Jr., et al. 2016. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 68(1):1-26. PMID: 26545940.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 64(5):625-39. PMID:22473917

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R. 2011. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;2:CD008794. PMID: 21328309

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P. 2009. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 7(4):CD007848. Review. PMID: 19821440



SOM Epilogue Menu